Solving Still's Disease

Save

Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.

Long-term JAK Inhibitor Treatment for Psoriatic Arthritis (PsA)

Save

Read for an overview of long-term results from SELECT-PsA 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory PsA patients.

An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

Save

Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are disorders of the immune system driven primarily by dysregulated T cells. Studies suggest that the Interleukin (IL)-23/Th-17 axis is one of the pathways involved in the pathogenesis of PsO and PsA.

Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Save

Leading experts from the SLE Educators' Network take us through the pathophysiology of SLE as we understand it today, and discuss the need to change the course of disease as a key treatment goal.

The Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)

Save

Read for an overview of results from SELECT-AXIS 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory AS patients.

The Future of PsA

Save

As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Save

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Save

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis

Save

Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Save

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

Comorbidities in axSpA: A Focus on Cardiovascular Features

Save

Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.